Vismodegib efficacy in unresectable trichoblastic carcinoma: A multicenter study of 16 cases
Authors:
- 1 June 2022
- journal article
- letter
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 86 (6) , 1365-1366
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Développement, mise en œuvre et objectifs de CARADERM, réseau national cancers cutanés rares – partie carcinomes annexielsAnnales de Dermatologie et de Vénéréologie, 2019
- Identification of potentially druggable molecular alterations in skin adnexal malignanciesThe Journal of Dermatology, 2019
- Vismodegib induces significant clinical response in locally advanced trichoblastic carcinomaBritish Journal of Dermatology, 2015
- Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trialThe Lancet Oncology, 2015
- PHLDA1, a Follicular Stem Cell Marker, Differentiates Clear-Cell/Granular-Cell Trichoblastoma and Clear-Cell/Granular Cell Basal Cell CarcinomaThe American Journal of Dermatopathology, 2014